Business Context and Reporting Period
Company: PAVmed Inc. (PAVM)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: PAVmed is a multi-product life sciences company operating as a parent entity for distinct subsidiaries, primarily Lucid Diagnostics (now an equity method investment) and Veris Health (majority-owned consolidated subsidiary). The company focuses on commercializing healthcare technologies, including the EsoGuard test (via Lucid) and the Veris Cancer Care Platform.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $8 | $1,010 |
| Operating Loss | $(5,446) | $(14,036) |
| Net Income (Loss) Attributable to PAVmed | $18,968 | $(15,212) |
| Net Income (Loss) to Common Stockholders | $17,695 | $(22,788) |
| Cash and Cash Equivalents (End of Period) | $2,700 | $25,536 |
| Net Cash Used in Operating Activities | $(1,581) | $(13,109) |
| Total Assets | $52,823 | $30,660 |
| Total Liabilities | $11,891 | $37,693 |
| Senior Secured Convertible Notes (Fair Value) | $6,600 | $29,100 |
Note: Q1 2025 Net Income is significantly driven by a $21.0 million unrealized gain on the equity method investment in Lucid Diagnostics and $3.15 million in management fee income.
Material Changes vs. Prior Period
- Deconsolidation of Lucid Diagnostics: Lucid was deconsolidated on September 10, 2024. Consequently, Q1 2025 revenue ($8k) and operating expenses are drastically lower than Q1 2024, which included Lucid's full operations ($1.0M revenue, $15.0M expenses).
- Debt Restructuring: The April 2022 Senior Convertible Note ($27.5M face value) was satisfied in full via an exchange for Series C Convertible Preferred Stock in January 2025. The remaining September 2022 Note balance was reduced to approximately $6.6M face value.
- Equity Method Investment Gain: PAVmed recognized a $21.0 million unrealized gain on its investment in Lucid Diagnostics due to an increase in Lucid's stock price (from $0.819 to $1.49 per share).
- Liquidity Position: Cash balances decreased from $25.5M in Q1 2024 to $2.7M in Q1 2025, despite a net increase in cash of $1.5M during the quarter, reflecting a lower starting balance and ongoing operational cash usage.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the Company's ability to continue as a going concern for 12 months following the issuance date. This is due to negative working capital ($6.1M), recurring operating losses, and dependence on future financing or revenue growth from Veris Health.
- Unusual Items:
- Deemed Dividends: The Company recognized $789k in deemed dividends related to Series C Preferred Stock modifications (conversion price reductions), which reduced net income available to common stockholders.
- Management Fee Income: $3.15 million recognized from the Management Services Agreement with Lucid Diagnostics.
- Nasdaq Compliance: The Company regained compliance with Nasdaq stockholders' equity requirements in February 2025 but received a notice in January 2025 regarding failure to meet the $1.00 minimum bid price requirement. The Company has until July 22, 2025, to regain compliance.
- Outlook: Future operations depend on controlling costs, increasing Veris Health revenues, and raising additional capital through equity or debt financings.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure additional financing given the $2.7M cash balance and negative working capital.
- Lucid Diagnostics Investment: Assess the volatility of the $46.6M equity method investment, which drove the majority of the reported net income.
- Debt Covenants: Confirm compliance with the September 2022 Senior Convertible Note covenants, noting the waivers granted through December 31, 2025.
- Nasdaq Listing: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by July 22, 2025, to avoid delisting.
- Preferred Stock Dilution: Review the terms of Series C Preferred Stock, including the temporary reduced conversion price of $0.40 and potential for significant dilution upon conversion.